SAN DIEGO, June 6 /PRNewswire/ -- SoluLinK, Inc. a leader in
biomolecular conjugation products and services for life science,
diagnostic, and nanotechnology markets, announced today the appointment of
David McCarty to its Board of Directors.
Mr. McCarty is currently the President and CEO of PanCel. He has held
senior positions in the health care industry for over 30 years. Most
recently, Mr. McCarty was President and CEO of NOVEX, which he successfully
merged with Invitrogen (a publicly-traded research products company) in
August 1999. He served on the Board of Directors of Invitrogen from August
1999 to August 2004. Prior to joining NOVEX in 1997, Mr. McCarty was the
President and CEO of Alexon Biomedical, a medical diagnostics company,
which he led to a successful financial turnaround and a profitable
strategic sale to Sybron International (now Apogent Technologies) in early
1997. His other professional experience includes senior operating positions
at Gen-Probe, Allergenetics, Calbiochem-Behring, Boehringer Mannheim
Diagnostics, and Hyland Diagnostics. Mr. McCarty received his B.S. in
chemistry from California State University at Northridge and his M.B.A.
from California State University at Long Beach.
"It is an honor to have David McCarty join SoluLinK's board. He is a
proven leader and brings market savvy and practical business expertise to
SoluLinK from his successful experience managing and directing multiple
bioscience companies," stated Steve DeGraw President and Chief Business
Officer of SoluLinK. "His knowledge of all aspects of the management of
rapidly growing life science companies will be invaluable to SoluLink's
SoluLinK is a privately held company located in San Diego, California.
SoluLinK develops, manufactures and markets products and services for the
conjugation of proteins, oligonucleotides, peptides, and antibodies to one
another, and to solid surfaces for array, research assay, diagnostic, and
therapeutics applications. SoluLinK's biotinylation reagent ChromaLink(R)
is an example of such products that that create, improve, and enable the
performance of arrays, research assays, diagnostics, and certain types of
therapeutics. SoluLinK markets these products directly and through
distributors and licensing partners world-wide.
SOURCE SoluLinK, Inc.